Latest Content

Patients with PD-L1-negative non-small cell lung cancer experienced longer progression-free survival with sac-TMT plus Keytruda compared with chemotherapy plus Keytruda in a phase 3 trial.

For National Hospice and Palliative Care Month, answers to common questions about how palliative care differs from hospice, who qualifies, what Medicare covers and how to find a program.

A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.

A breast cancer survivor shares how cancer turned gratitude into an everyday practice and why it's OK when the holidays bring both joy and grief this year.

Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.

HealthCare.gov open enrollment runs Nov. 1, 2026, to Jan. 15, 2027, and the 2027 out-of-pocket ceiling rises to $12,000. Here's what people with cancer should check before picking a plan.

After nearly a year of chemotherapy, a patient with stage 4 pancreatic cancer describes daily life and side effects on Rasonque (daraxonrasib).

For Lung Cancer Awareness Month, answers to common patient questions about biomarker testing in non-small cell lung cancer: which gene changes doctors look for, blood vs. tissue tests, insurance and retesting.

A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.

From a new chemotherapy combination to the first RAS-targeted pill, here's what five years of pancreatic cancer approvals mean for patients.

Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.

A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.

In the phase 2 MASTERPLAN trial, adding SBRT to chemotherapy lowered the rate of cancer returning near the pancreas from 52.0% to 20.2% at one year.